![]() |
![]() |
![]() |
![]() |
| Preventing HIV |
| Treating HIV |
| Living with HIV |
| For service providers |
| For health care providers |
| Access our services |
| Find organizations |
| News and events |
| About CATIE |
| Site map |
| Home |
| CATIE Ordering Centre |
|
Fact Sheets Indinavir (Crixivan) SummaryIndinavir is a type of anti-HIV drug called a protease inhibitor. The most common side effects of indinavir can include nausea, headache, diarrhea, vomiting, and weakness. Indinavir can also cause kidney stones, but drinking a minimum of 1.5 litres of water daily, in addition to your regular intake of other fluids, can help reduce this complication. What is indinavir?Indinavir, sold under the brand name Crixivan, is a type of anti-HIV drug (antiretroviral) called a protease inhibitor (PI). Indinavir is used in combination with other anti-HIV drugs to treat (but not cure) HIV/AIDS. How does indinavir work?To explain how indinavir works, we need to first tell you some information about HIV. When HIV infects a cell, it takes control of that cell. HIV then forces the cell to make many more copies of the virus. In order to make these copies, the cell uses proteins called enzymes. When the activity of these enzymes is reduced or blocked, production of HIV slows or stops. Indinavir belongs to a group or class of drugs called protease inhibitors. Indinavir interferes with an enzyme called protease, which is used by HIV-infected cells to make new viruses. Since indinavir inhibits, or reduces the activity of this enzyme, this drug causes HIV-infected cells to produce fewer viruses. How do people with HIV/AIDS use indinavir?Indinavir is used in combination with several other anti-HIV drugs, usually nukes (nucleoside analogues), and sometimes including drugs from other classes such as non-nukes (non-nucleoside reverse transcriptase inhibitors). Combinations such as this are called highly active antiretroviral therapy, or HAART. For more information on HAART, see CATIE's Practical Guide to HAART for People Living with HIV/AIDS at www.catie.ca/PG_HAART_e.nsf. For many people with HIV/AIDS (PHAs), the use of HAART has increased their CD4+ cell counts and decreased the amount of HIV in their blood (viral load). These beneficial effects help to reduce the risk of developing a life-threatening infection. Neither indinavir nor any other anti-HIV medication is a cure for HIV/AIDS. It is therefore important that you do the following:
Warnings1. Kidney stones
Of course, if you have persistent diarrhea or vomiting, you should contact your doctor.
Side effects1. General 2. Bilirubin
Together with these physical changes, lab tests of your blood may detect the following:
The precise causes of the HIV lipodystrophy syndrome are not clear and are difficult to understand because in some PHAs there may be one or more aspects of the syndrome taking place. For instance, some people may experience fat wasting, others fat gain, and others may experience both fat gain and wasting. What is becoming increasingly clear is that unfavourable changes in the lab readings of glucose, cholesterol, and triglycerides over a period of several years increase the risk of diabetes and cardiovascular disease. So far, however, the many benefits of HAART are much greater than the increased risk of cardiovascular disease or other side effects. Maintaining a normal weight, eating a healthy diet, exercising regularly, and quitting smoking are all important in helping you to reduce your risk of diabetes, heart disease, and other complications. Regular visits to your doctor for checkups and blood tests are a vital part of staying healthy. If necessary, your doctor can prescribe lipid-lowering therapy. Researchers are studying the lipodystrophy syndrome to try to discover ways of helping PHAs avoid or reduce this problem. To find out more about options for managing aspects of the lipdystrophy syndrome, see CATIE's Practical Guide to HIV Drug Side Effects at www.catie.ca/sideeffects_e.nsf. Drug interactionsAlways consult your doctor and pharmacist about taking any other prescription or non-prescription medication, including herbs, supplements, and street drugs. Some drugs can interact with indinavir, increasing or decreasing its levels in your body. Increased drug levels can cause you to experience side effects or make pre-existing side effects worse. On the other hand, if drug levels become too low, HIV can develop resistance and your future treatment options may be reduced. It may also be necessary to avoid drugs that do not affect indinavir drug levels, but cause similar side effects. If you must take a drug that has the potential to interact with your existing medications, your doctor can do the following:
Drug interactions for indinavirThe following drugs interact or have the potential to interact with indinavir. These lists are not exhaustive. The manufacturer recommends that the following drugs should not be taken by people using indinavir, because this could lead to serious (or life-threatening) interactions.
The following drugs can increase levels of indinavir in your body:
The following drugs can decrease levels of indinavir in the blood:
The following supplements may decrease levels of indinavir in your blood:
In both sets of studies (milk thistle and vitamin C) subjects were taking indinavir as the sole PI in their regimen. Results may be different when indinavir is taken in combination with other PIs, such as ritonavir. Resistance and cross-resistanceOver time, as new copies of HIV are made in the body, the virus changes its structure. These changes are called mutations and can cause HIV to resist the effects of anti-HIV drugs, which means those drugs will no longer work for you. Combining indinavir with at least two other anti-HIV drugs delays the development of drug resistance. To reduce the risk of developing drug resistance, all anti-HIV drugs should be taken every day exactly as prescribed and directed. If doses are delayed, missed, or not taken as prescribed, levels of indinavir in the blood may fall too low. If this happens, resistant virus can develop. If you find you are having problems taking your medications as directed, speak to your doctor and nurse about this. They can find ways to help you. When HIV becomes resistant to one drug in a class, it sometimes becomes resistant to other drugs in that class. This is called cross-resistance. Feel free to talk with your doctor about your current and future treatment options. To help you decide what these future therapies might be, at some point your doctor can have a small sample of your blood analysed using resistance testing. Should HIV in your body become resistant to indinavir your doctor, with the help of resistance testing, can help put together a new treatment regimen for you. Dosage and formulationsBecause of the complex regimens and side effects associated with the use of indinavir, this drug is rarely used in Canada and other high-income countries. Still, if indinavir is prescribed in Canada, here is some information. Indinavir is available as 200 mg and 400 mg capsules. AvailabilityIndinavir is licensed in Canada for the treatment of HIV infection in adults, in combination with other anti-HIV drugs. Your doctor can tell you more about the availability and coverage of indinavir in your region. CATIE’s online module Federal, Provincial and Territorial Drug Access Programs (on CATIE’s website at www.catie.ca/eng/Publications/drugaccess/drugaccessIndex.shtml) also contains information about Canadian drug coverage.” References Boyd M. Indinavir: the forgotten HIV-protease inhibitor. Does it still have a role? Expert Opinion in Pharmacotherapy 2007;8(7):957-964. Slain D, Amsden JR, Kahkoo RA, et al. Effect of high-dose vitamin C on the steady-state pharmacokinetics of the protease inhibitor indinavir in healthy volunteers. Pharmacotherapy 2005;25(2):165-170. Burger D, Boyd M, Duncombe C, et al. Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients. Journal of Antimicrobial Chemotherapy 2003;51(5):1231-1238. Campo RE, Moreno JN, Suarez G, et al. Efficacy of indinavir-ritonavir-based regimens in HIV-1-infected patients with prior protease inhibitor failures. AIDS. 2003;17(13):1933-1939. DiCenzo R, Shelton M, Jordan K, et al. Coadministration of milk thistle and indinavir in healthy subjects. Pharmacotherapy 2003;23(7):866-870. Dieleman JP, van Rossum AM, Stricker BC, et al. Persistent leukocyturia and loss of renal function in a prospectively monitored cohort of HIV-infected patients treated with indinavir. Journal of Acquired Immune Deficiency Syndromes 2003;32(2):135-142. Dragsted UB, Gerstoft J, Pedersen C, et al. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial. Journal of Infectious Diseases 2003;188(5):635-642. Hirsch MS, Steigbigel RT, Staszewski S, et al. Long-term efficacy, safety, and tolerability of indinavir-based therapy in protease inhibitor-naïve adults with advanced HIV infection. Clinical Infectious Diseases 2003;37(8):1119-1124. Slain D, Amsden JR, Kakoo RA, et al. Effect of high-dose vitamin C on the steady-state pharmacokinetics of the protease inhibitor indinavir in healthy volunteers. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, September 14-17, 2003. Abstract 1610. Aarnoutse RE, Grintjes KJ, Telgt DS, et al. The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers. Clinical Pharmacology and Therapeutics 2002;71(1):57-67. de Araujo M, Seguro AC. Trimethoprim-sulfamethoxazole (TMP/SMX) potentiates indinavir nephrotoxicity. Antiviral Therapy 2002;7(3):181-184. Piscitelli SC, Formentini E, Burstein AH, et al. Effect of milk thistle on the pharmacokinetics of indinavir in healthy volunteers. Pharmacotherapy 2002;22(5):551-556. Young B, Fischl MA, Wilson HM, et al. Open-label study of a twice-daily indinavir 800-mg/ritonavir 100-mg regimen in protease inhibitor-naive HIV-infected adults. Journal of Acquired Immune Deficiency Syndromes. 2002;31(5):478-482. | |
|
2007 Author(s): Hosein SR | |
|
|
|
Decisions about particular medical treatments should always be made in consultation with a qualified medical practitioner who is knowledgeable about HIV-related illness and the treatments in question. MORE | |